[1] Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm[J]. Nat Rev Cancer, 2009, 9(3): 153-166. DOI: 10.1038/nrc2602.
[2] Banyai G, Badi F, Coudreuse D, et al. Cdk1 activity acts as a quantitative platform for coordinating cell cycle progression with periodic transcription[J]. Nat Commun, 2016, 7: 11161. DOI: 10.1038/ncomms11161.
[3] Su J, Zhou H, Tao Y, et al. HCdc14A is involved in cell cycle regulation of human brain vascular endothelial cells following injury induced by high glucose, free fatty acids and hypoxia[J]. Cell Signal, 2015, 27(1): 47-60. DOI: 10.1016/j.cellsig.2014.10.003.
[4] Risal S, Adhikari D, Liu K. Animal models for studying the in vivo functions of cell cycle CDKs[J]. Methods Mol Biol, 2016, 1336: 155-166. DOI: 10.1007/978-1-4939-2926-9_13.
[5] Wang Q, Li M, Zhang X, et al. Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis[J]. Exp Mol Pathol, 2016, 100(3): 514-521. DOI: 10.1016/j.yexmp.2016.05.001.
[6] Schwartz BE, Larochelle S, Suter B, et al. Cdk7 is required for full activation of Drosophila heat shock genes and RNA polymerase Ⅱ phosphorylation in vivo[J]. Mol Cell Biol, 2003, 23(19): 6876-6886.
[7] 冀全博, 徐小洁, 张强, 等. 人细胞周期蛋白H基因的真核表达载体构建和表达及功能检测[J]. 细胞与分子免疫学杂志, 2014, 30(9): 941-943. DOI: 10.13423/j.cnki.cjcmi.007091.
[8] Pitts TM, Davis SL, Eckhardt SG, et al. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors[J]. Pharmacol Ther, 2014, 142(2): 258-269. DOI: 10.1016/j.pharmthera.2013.12.010.
[9] Ali S, Heathcote DA, Kroll SH, et al. The development of a selective cyclindependent kinase inhibitor that shows antitumor activity[J]. Cancer Res, 2009, 69(15): 6208-6215. DOI: 10.1158/00085472.CAN090301.
[10] Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor[J]. Nature, 2014, 511(7511): 616-620. DOI: 10.1038/nature13393.
[11] 陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况[J]. 中国肿瘤临床, 2015, 42(13): 668674. DOI: 10.3969/j.issn.10008179.20150571.
[12] 龚巍巍, 罗胜兰, 胡如英, 等. 2005—2010年浙江省女性乳腺癌、宫颈癌与卵巢癌生存率分析[J]. 中华预防医学杂志, 2014, 48(5): 366-369. DOI: 10.3760/cma.j.issn.02539624.2014.05.007.
[13] LaubySecretan B, Scoccianti C, Loomis D, et al. 国际癌症研究机构工作组乳腺癌筛查简报[J]. 中国全科医学, 2015, 18(27): 3265-3267.
[14] 谢杨, 周雪妍, 郝海平, 等. 核受体FXR代谢调控作用及肿瘤细胞增殖机制研究进展[J]. 生理学报, 2014, 66(2): 252-258. DOI: 10.13294/j.aps.2014.0030.
[15] Ganuza M, Santamaría D. Cdk7: open questions beyond the prevailing model[J]. Cell Cycle, 2012, 11(19): 3519-3520. DOI: 10.4161/cc.21888.
[16] Liang YC, Tsai SH, Chen L, et al. Resveratrolinduced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells[J]. Biochem Pharmacol, 2003, 65(7): 1053-1060.
[17] Zhang S, Liu JP, Xu FQ, et al. Gene silencing of MAT1 mediated by siRNA inhibits cell proliferation and invasion in pancreatic cancer in vitro[J]. ChinGer J Clin Oncol, 2008, 7(5): 280-282. DOI: 10.1007/s10330-008-0020-4. |